reversible decrease of portal venous flow in cirrhotic patients a positive side effect of sorafenib可逆门户静脉流减少肝硬化患者索拉非尼的一个积极的副作用.pdfVIP

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib 1,2,3 ´ 3,4 1,2,3 1,2,3 3,4 Romain Coriat *, Herve Gouya , Olivier Mir , Stanislas Ropert , Olivier Vignaux , Stanislas Chaussade3,5, Philippe Sogni3,6, Stanislas Pol3,6, Benoit Blanchet3,7, Paul Legmann3,4., Franc¸ois Goldwasser1,2,3. ˆ 1 Center for Research on Angiogenesis Inhibitors (CERIA), Hopital Cochin, AP-HP, Paris, France, 2 Department of Medical Oncology, Teaching Hospital Cochin, Paris, ´ France, 3 Universite Paris Descartes, Paris, France, 4 Department of Radiology, Teaching Hospital Cochin, Paris, France, 5 Gastroenterology Unit, Teaching Hospital Cochin, ˆ ˆ Paris, France, 6 Liver Unit and Inserm U-567, Hopital Cochin, AP-HP, Paris, France, 7 Laboratory of Pharmacology, Hopital Cochin, AP-HP, Paris, France Abstract Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a